Open AccessChanges in Inflammation and QoL After a Single Dose of Infliximab During Ongoing IBD Treatment
Author(s) -
DeBoer Mark D.,
Barnes Barrett H.,
Stygles Nicholas A.,
Sutphen James L.,
Borowitz Stephen M.
Publication year - 2012
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 131
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0b013e3182382ee3
Subject(s) - medicine , infliximab , asymptomatic , context (archaeology) , quality of life (healthcare) , inflammatory bowel disease , observational study , randomized controlled trial , disease , gastroenterology , physical therapy , paleontology , nursing , biology
Background and Objectives: Infliximab is used increasingly as maintenance therapy for inflammatory bowel disease (IBD); however, the effects of a single maintenance dose of infliximab are unclear with respect to the quality of life and hormones related to growth and puberty. The aim of the present study was to determine the time course of inflammatory, hormonal, and quality‐of‐life changes following a single dose of infliximab in the context of ongoing therapy, as related to presence of IBD symptoms at time of administration. Methods: Children and adolescents with IBD receiving ongoing therapy with infliximab for clinical indications were recruited. The Pediatric Crohn's Disease Activity Index was determined at baseline and laboratory measures of high‐sensitivity C‐reactive protein (hsCRP) and hormones of growth and puberty were determined on days 0, 2, and 14. IBD‐related quality of life (IMPACT III questionnaire) was tested on days 0 and 14. Subjects who had symptoms of IBD were compared with asymptomatic subjects. Results: Subjects overall and in the symptomatic group exhibited improved hsCRP by day 2 following treatment. Symptomatic subjects had higher Pediatric Crohn's Disease Activity Index scores and lower quality‐of‐life scores than asymptomatic subjects on day 0, whereas at day 14 there were no significant differences in quality‐of‐life scores between the 2 groups. Conclusions: Even in the context of ongoing treatment, a single dose of infliximab results in decreased hsCRP, an improvement that is particularly noted among subjects who are symptomatic at the time of treatment. Although randomized trials are needed, these observational data may assist clinicians, patients, and families regarding expectations about timing and extent of these changes following a single treatment dose.